Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Curis has selected an orally available, synthetic small molecule inhibitor of heat shock protein 90 as a development candidate from its targeted cancer drug development platform.
Subscribe to our email newsletter
In both laboratory and animal testing, CUDC-305 demonstrated high potency in vitro and in vivo across a wide range of cancers. Tumor regression has also been observed after treatment of CUDC-305 in mouse xenograft models of breast, non-small cell lung, gastric cancer and glioblastoma brain cancers.
In addition to demonstrating potent efficacy across a broad range of cancers in preclinical cancer models, CUDC-305 exhibits promising pharmacological features, particularly its high oral bioavailability, high tumor penetration and extended tumor retention.
Dan Passeri, president and CEO of Curis, said: “We are pleased to enter this field with our own novel and proprietary compound, CUDC-305, which not only has met our rigorous internal metrics for development candidate selection, but has also demonstrated pharmacological properties that, while based upon early results, we believe may enable it to achieve best-in-class among Hsp90 inhibitors.”